$APUS, $AVBP, $JUNS & $OSTX: four headlines, four different tests

On October 5, Apimeds’ wholly owned subsidiary MindWave Innovations announced a two-year agreement, effective October 4, with BlockAssure to build and operate AssureChain, a network for insurance and reinsurance operations. MindWave is to receive contracted development fees, payable quarterly, and 20% of the total supply of a planned AssureCoin token when the token is created; operating and maintenance fees remain to be negotiated. Development is planned over four quarters, with milestones and acceptance testing for each module. MindWave’s October 5 release, distributed by GlobeNewswire.

The stock had already closed October 5 at $4.59, up from $3.22, and added roughly 56% more by the October 6 snapshot, on volume above 39 million shares.

That is a commercial technology story within a company that appears on biotech screens. It does not establish a clinical advance for Apimeds’ drug pipeline. The distinction matters when comparing $APUS with a company reporting patient outcomes: the two stocks may occupy the same scanner, while their valuation questions have little in common.

Research interpretation: the follow-up work belongs in contract economics and execution. Development payments, accepted project milestones and any disclosed operating economics will be more useful than assigning an assumed dollar value to a token that does not yet exist. A large percentage move alone cannot establish how much durable value the agreement adds.

ArriVent announced that the Phase 3 FURVENT trial of firmonertinib in previously untreated EGFR exon 20 insertion-mutant non-squamous non-small cell lung cancer did not meet its primary endpoint of progression-free survival assessed by blinded independent central review.

The 240 mg arm recorded median PFS of 11.0 months versus 9.5 months for platinum-based chemotherapy with pemetrexed, with a hazard ratio of 0.75 (95% CI 0.55–1.02) and p=0.0654. The 160 mg arm recorded 8.4 months. The study enrolled 398 patients globally. The company described favorable signals on some secondary measures and a trend toward improved overall survival, with OS data not yet mature. Management said it is evaluating the full dataset to determine the most appropriate development path. ArriVent’s October 6 release · NCT05607550.

The stock, which closed October 5 at $28.46, was near $14.34 at the snapshot, a decline of about 50%.

Research interpretation: the primary-endpoint failure is the controlling fact. Secondary results may inform further research, but they do not turn this trial into a successful pivotal readout. The next assessment should examine management’s proposed path, the resources needed to pursue it and what evidence could support that path. A lower share price, by itself, does not resolve any of those questions.

Jupiter announced the first patient dosing in RESET, its multicenter Phase 2a study of JOTROL in Parkinson’s disease. The randomized, double-blind, placebo-controlled study plans approximately 30 participants, randomized 1:1:1 to two JOTROL dose levels or placebo, with 12 weeks of oral treatment. Its primary objectives are safety, tolerability and pharmacokinetics, including JOTROL exposure in plasma and cerebrospinal fluid; biomarker and clinical assessments are additional measures.

The company also retained Tungsten Advisors to explore asset sales or licensing, partnerships, business combinations and other transactions. No transaction was announced, and the company cautioned that there can be no assurance the process will produce one. Jupiter’s October 6 release.

Research interpretation: this is a fresh, identifiable catalyst, with separate clinical and corporate components. First dosing advances development but says nothing yet about treatment efficacy in Parkinson’s patients. Likewise, engaging an adviser starts a process rather than establishing a sale price. Enrollment progress, eventual patient data and signed transaction terms are the evidence to watch.

OS Therapies reported final three-year overall survival of 72.7% for patients treated with OST-HER2 (Herlystic) in its Phase 2b study in fully resected pulmonary metastatic osteosarcoma, compared with 45.8% in historical controls. The company reported p=0.0006, 41 enrolled patients and four patients lost to follow-up.

The critical limitation is the historical comparator: this was not a randomized comparison against a concurrent control group. The company intends to complete in the fourth quarter of 2026 a U.S. BLA submission under the Accelerated Approval pathway and conditional marketing authorization applications in Europe, the U.K. and Australia, and says it is aligned with regulators on the design of the confirmatory Phase 3 trial. The company notes that starting the confirmatory Phase 3 is a prerequisite for Accelerated Approval and the conditional authorizations. Those remain planned steps, not approvals. OS Therapies’ October 6 release.

The stock opened at $1.71 but was at $1.546 at the snapshot, below the $1.60 October 5 close, with about 5.3 million shares traded.

Research interpretation: the update deserves clinical and regulatory attention, even though the initial price response faded. The next diligence questions concern comparability of the historical patients, treatment of missing follow-up and the confirmatory program’s execution. The observed reversal cannot, on its own, tell us why investors sold.